HEALTH

HBI introduces DreamKeeper 400 for insomnia

BY Michael Johnsen

FREMONT, Calif. HBI USA on Wednesday announced the launch of its insomnia device DreamKeeper 400, which uses its proprietary breath synchronization program and parallelized electroStatic field technology to rebuild the user’s biological clock and improve the quality and duration of sleep.

According to clinical trials conducted by the company, 70 percent of users reported improvements in sleep duration and quality within three weeks of using the device.

Users position the DreamKeeper on the inner wrist a half-hour prior to going to bed for a period of approximately three weeks. The breath synchronization program guides users to slow down their breathing, to calm them down and prepare for sleep.

Suggested retail for the DreamKeeper 400 is $149.99, and is currently available online through Target and Amazon.com.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

CRN study finds that nearly four-fifths of doctors recommend supplements

BY Michael Johnsen

WASHINGTON The majority of physicians—79 percent—recommend supplements to their patients, according to the “Life…supplemented” Healthcare Professionals Impact Study, conducted by the Council for Responsible Nutrition, that was released Wednesday.

Bone health was the leading health reason physicians recommend supplements—33 percent of physicians recommended bone health supplements to their patients—followed by supplements for overall health, joint health, heart health and to maintain a healthy cholesterol.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

FDA announces meeting to explore OTC flu treatments

BY Michael Johnsen

ROCKVILLE, Md. Treatments to be used in the event of a pandemic flu epidemic may one day be available over-the-counter. The Food and Drug Administration on Tuesday announced a joint meeting of the Antiviral Drugs Advisory Committee and the Nonprescription Drugs Advisory Committee in the Federal Register to determine the types of studies and trial designs needed for an influenza antiviral MedKit for the treatment or prevention of pandemic influenza.

The meeting will be held Oct. 29 at the Hilton in Rockville, Md.

According to the announcement, committee members will be tasked with providing advice on issues such as the role of personal MedKits, home stockpiling, non-prescription availability of influenza medications and interfaces of home readiness with public health systems.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?